

Second international workshop on interim- PET in lymphoma

Menton (France), Palais de l'Europe, April 8-9th, 2010

Under the auspices of GELA, IIL, EORTC, SFMN

Organization Committee

M.Meignan (France), A.Gallamini (Italy), C.Haioun (France)



Advisory board

**A.Polliack (Israel), N.Mounier (France), H.Tilly (France),
S.Barrington, (U.K), A.Engert (Germany), P.Bourguet (France),
M.Hutchings(Denmark), O.Hoekstra (Netherlands), S.Stroobants
(Belgium), O.Mundler (France), J.Seymour (Australia).**

We are pleased to announce the Second International Workshop on interim PET in lymphoma, to be held in Menton (French Riviera), in April 8-9th 2010.

The first international workshop, organized under the auspices of the GELA by Michel Meignan (Créteil, France), Andrea Gallamini (Cuneo, Italy) and Corinne Haioun (Créteil, France) was held in Deauville, France in April 2009. The aim was twofold: to reach a consensus on criteria for interim PET interpretation in lymphoma and to launch international validation studies (IVS) in an attempt to validate these rules in Hodgkin (HL) and Diffuse Large B-Cell Lymphoma (DLCL). The report of this workshop is available in *Leukemia & Lymphoma* 2009; 50:1267-60.

In Menton, more than 50 experts in the field will participate to the closed meeting on Thursday and will attend the open session in Friday. During the open session the invited international experts, Nuclear Medicine physicians and Haematologists, will present the “state of the art”, moving from the pioneer studies up to the last achievements, and will focus on a number of “hot” and unsettled issues in interim PET in lymphoma. The clinical trials that are running worldwide at this writing aimed to assess the role of an interim-PET response adapted strategy will be shared with the audience, as well the preliminary results of the IVS on HL and DLCL. The experts will also discuss the validity of the Deauville consensus criteria. We hope to see you and share with you a fruitful meeting.

Michel Meignan, michel.meignan@hmn.aphp.fr
Corinne Haioun, corinne.haioun@hmn.aphp.fr
Andrea Gallamini, gallamini.a@ospedale.cuneo.it

Experts

Nuclear Medicine:

S. Bardet (France), S. Barrington (UK), F. Bodere (France), A. Biggi (Italy), R. Boellaards (Netherlands), P. Bourguet (France), L. Brepoels (Belgium), A. Buck (Germany), S. Chauvie (Italy), M. O’Doherty (UK), L. Ceriani (Switzerland), L. Giovanella (Switzerland), R. Hicks (Australia), O. Hoekstra (Netherlands), E. Itti (France), L. Kostakoglu (US), M. Meignan (France), S. Muller (Germany), O. Mundler (France), S. Stroobandts (Belgium), P. Vera (France), T. Van der Borcht (Belgium)

Haematology:

M. Andre (Belgium), A. Avigdor (Israel), E. Brusamolino (Italy), P. Brice (France), C. Caballero (Spain), O. Casasnovas (France), B. Cheson (US), E. Dann (Israel), A. Engert (Germany), M. Federico (Italy), C. Fermé (France), A. Gallamini (Italy), C. Gisselbrecht (France), C. Haioun (France), M. Hutchings (Denmark), P. Johnson (UK), Y. Kasamon (US), A. Levis (Italy), G. Mikhaeel (UK), F. Morschhauser (France), N. Mounier (France), A. Polliack (Israel), M. Pfreundschuh (Germany), J. Radford (UK), J. Raemaekers (Netherlands), L. Rigacci (Italy), L. Sehn (Canada), J. Seymour (Australia), T. Terasawa (US, Japan), C. Thieblemont (France), H. Tilly (France), U. Vitolo (Italy), J.M. Zaucha (Poland), J. Zijlstra (Netherlands)

PROGRAM



Friday April 9th (Palais de l'Europe, Menton)

08.00 – Forewords (general) : M. Meignan - A. Gallamini - C. Haioun

08.30 - 09.30 : New frontiers

Chairmen: A. Levis – L. Giovanella

08.30 – 09.00 : L. Kostakoglu :

Has the interim-PET retained its prognostic role in lymphoma?

09.00 – 09.30 : Y. Kasamon :

How can we incorporate PET in clinical prospective trials (USA experience)?

09.30 - 11.45 : Current studies with interim-PET - Hodgkin Lymphoma

Chairmen : A. Polliack – F. Boderé

Chairmen : N. Mounier – S. Bardet

09.30 - 10.00 : Early HL

- **M Andre, J. Raemaekers, M Federico : The H10 study**
- **J. Radford : The RAPID study**

10.00 - 10.15 : Coffee break

10.15 – 11.45 : Advanced-stage HL

- **P. Johnson : The RATHL study**
- **A. Gallamini : The GITIL HD 0607 study**
- **E. Brusamolino : The IIL HD 0801 study**
- **M. Hutchings : Danish Paediatric study**
- **O. Casasnovas/C. Fermé, P. Brice : The GELA study**
- **A. Engert : The GHSG HD 18 study**
- **E. Dann : The Haifa study**
- **J. M. Zaucha : The Polish study**
- **L. Ceriani : The Swiss study**

12.00 – 12.45 : Round table

C. Haioun(GELA) - U Vitolo (IIL) - M. Pfreundschuh (DNHLSG) - G. Mikhaeel (MRC)
Is time for an European PET-response adapted protocol for DLBCL?

13.00 - 14.00 : Lunch

14.00 - 15.00 : Open Issues in interim PET

Chairmen : M. Federico - S. Barrington

14.00 - 14.30 : L. Brepoels :

Interim PET (what can we learn from animal studies?) with emphasis on the effect of drugs.

14.30 - 15.00 : R. Hicks :

Interim PET in solid tumours

15.00 - 15.10 : Coffee break

15.10 - 16.30 : Current studies with interim-PET - Non Hodgkin Lymphoma

Chairmen : C. Gisselbrecht - Van der Boght

Part 1: DLBCL

- **U Duhrsen : The PETAL study**
- **G. Mikhaeel : The BMC study**
- **D. Caballero : The GELTAMO Study**
- **O. Casasnovas, F. Morschhauser : The LNH073B study**
- **L. Sehn : BCCA study**
- **L. Rigacci : The IIL study**

Part 2: Follicular lymphoma

- **B. Cheson: Follicular lymphoma : the CALGB study**
- **M. Meignan : Follicular Lymphomas, the PCR06002 study**

16.30 – 17.30: International Validation Studies

Chairmen: B. Cheson - J. Seymour

16.30 - 16.45: A. Gallamini:

International validation Study in HL

16.45 - 17.00: M. Meignan:

International validation Study in DLBCL

17.00 Next steps M. Meignan

Conclusions: next steps



